ENO2 and lung carcinoma: In terms of clinical implications in the diagnosis and personalized treatment of the microcellular lung cancer, the screening test of whole blood for these tumor biomarkers aims at the early effective personalized treatment and the pursuit of therapeutic efficiency by monitoring the levels of NSE and CEA found in whole blood.